vs
MESA LABORATORIES INC（MLAB）与森萨塔科技（ST）财务数据对比。点击上方公司名可切换其他公司
森萨塔科技的季度营收约是MESA LABORATORIES INC的14.1倍（$917.9M vs $65.1M）。森萨塔科技净利率更高（6.9% vs 5.6%，领先1.3%）。MESA LABORATORIES INC同比增速更快（3.6% vs 1.1%）。森萨塔科技自由现金流更多（$151.9M vs $18.0M）。过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -4.5%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
森萨塔科技控股有限公司是全球领先的工业科技企业，主营传感器、电气保护及控制解决方案的研发、生产与销售，产品覆盖汽车、工业、航空航天、暖通空调、电信等多个下游领域，服务全球制造类企业客户。
MLAB vs ST — 直观对比
营收规模更大
ST
是对方的14.1倍
$65.1M
营收增速更快
MLAB
高出2.5%
1.1%
净利率更高
ST
高出1.3%
5.6%
自由现金流更多
ST
多$133.9M
$18.0M
两年增速更快
MLAB
近两年复合增速
-4.5%
损益表 — Q3 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $917.9M |
| 净利润 | $3.6M | $63.2M |
| 毛利率 | 64.2% | 29.0% |
| 营业利润率 | 12.2% | 10.9% |
| 净利率 | 5.6% | 6.9% |
| 营收同比 | 3.6% | 1.1% |
| 净利润同比 | 316.6% | 992.7% |
| 每股收益（稀释后） | $0.65 | $0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABST
| Q4 25 | $65.1M | $917.9M | ||
| Q3 25 | $60.7M | $932.0M | ||
| Q2 25 | $59.5M | $943.4M | ||
| Q1 25 | $62.1M | $911.3M | ||
| Q4 24 | $62.8M | $907.7M | ||
| Q3 24 | $57.8M | $982.8M | ||
| Q2 24 | $58.2M | $1.0B | ||
| Q1 24 | $58.9M | $1.0B |
净利润MLABST
| Q4 25 | $3.6M | $63.2M | ||
| Q3 25 | $2.5M | $-162.5M | ||
| Q2 25 | $4.7M | $60.7M | ||
| Q1 25 | $-7.1M | $69.9M | ||
| Q4 24 | $-1.7M | $5.8M | ||
| Q3 24 | $3.4M | $-25.0M | ||
| Q2 24 | $3.4M | $71.7M | ||
| Q1 24 | $-254.6M | $76.0M |
毛利率MLABST
| Q4 25 | 64.2% | 29.0% | ||
| Q3 25 | 61.5% | 27.8% | ||
| Q2 25 | 62.0% | 30.3% | ||
| Q1 25 | 61.8% | 29.9% | ||
| Q4 24 | 63.3% | 27.1% | ||
| Q3 24 | 61.3% | 28.6% | ||
| Q2 24 | 64.0% | 30.0% | ||
| Q1 24 | 62.1% | 31.5% |
营业利润率MLABST
| Q4 25 | 12.2% | 10.9% | ||
| Q3 25 | 7.8% | -13.2% | ||
| Q2 25 | 5.1% | 14.6% | ||
| Q1 25 | 2.4% | 13.4% | ||
| Q4 24 | 9.2% | 8.1% | ||
| Q3 24 | 6.1% | -20.3% | ||
| Q2 24 | 9.6% | 12.5% | ||
| Q1 24 | -460.6% | 14.4% |
净利率MLABST
| Q4 25 | 5.6% | 6.9% | ||
| Q3 25 | 4.1% | -17.4% | ||
| Q2 25 | 8.0% | 6.4% | ||
| Q1 25 | -11.4% | 7.7% | ||
| Q4 24 | -2.7% | 0.6% | ||
| Q3 24 | 5.9% | -2.5% | ||
| Q2 24 | 5.8% | 6.9% | ||
| Q1 24 | -432.2% | 7.6% |
每股收益（稀释后）MLABST
| Q4 25 | $0.65 | $0.45 | ||
| Q3 25 | $0.45 | $-1.12 | ||
| Q2 25 | $0.85 | $0.41 | ||
| Q1 25 | $-1.30 | $0.47 | ||
| Q4 24 | $-0.31 | $0.05 | ||
| Q3 24 | $0.63 | $-0.17 | ||
| Q2 24 | $0.62 | $0.47 | ||
| Q1 24 | $-47.26 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $573.0M |
| 总债务越低越好 | $68.4M | $2.8B |
| 股东权益账面价值 | $186.7M | $2.8B |
| 总资产 | $434.8M | $6.8B |
| 负债/权益比越低杠杆越低 | 0.37× | 1.02× |
8季度趋势，按日历期对齐
现金及短期投资MLABST
| Q4 25 | $29.0M | $573.0M | ||
| Q3 25 | $20.4M | $791.3M | ||
| Q2 25 | $21.3M | $661.8M | ||
| Q1 25 | $27.3M | $588.1M | ||
| Q4 24 | $27.3M | $593.7M | ||
| Q3 24 | $24.3M | $506.2M | ||
| Q2 24 | $28.5M | $1.0B | ||
| Q1 24 | $28.2M | $460.4M |
总债务MLABST
| Q4 25 | $68.4M | $2.8B | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | $3.2B | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABST
| Q4 25 | $186.7M | $2.8B | ||
| Q3 25 | $178.5M | $2.7B | ||
| Q2 25 | $172.5M | $2.9B | ||
| Q1 25 | $159.8M | $2.8B | ||
| Q4 24 | $155.2M | $2.9B | ||
| Q3 24 | $161.5M | $3.0B | ||
| Q2 24 | $150.7M | $3.0B | ||
| Q1 24 | $145.4M | $3.0B |
总资产MLABST
| Q4 25 | $434.8M | $6.8B | ||
| Q3 25 | $430.4M | $7.1B | ||
| Q2 25 | $435.7M | $7.3B | ||
| Q1 25 | $433.3M | $7.2B | ||
| Q4 24 | $433.3M | $7.1B | ||
| Q3 24 | $454.1M | $7.3B | ||
| Q2 24 | $440.4M | $8.2B | ||
| Q1 24 | $446.8M | $7.6B |
负债/权益比MLABST
| Q4 25 | 0.37× | 1.02× | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | 1.11× | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $201.5M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $151.9M |
| 自由现金流率自由现金流/营收 | 27.7% | 16.6% |
| 资本支出强度资本支出/营收 | 1.1% | 5.4% |
| 现金转化率经营现金流/净利润 | 5.17× | 3.19× |
| 过去12个月自由现金流最近4个季度 | $37.9M | $490.3M |
8季度趋势，按日历期对齐
经营现金流MLABST
| Q4 25 | $18.8M | $201.5M | ||
| Q3 25 | $8.2M | $159.9M | ||
| Q2 25 | $1.9M | $140.9M | ||
| Q1 25 | $12.7M | $119.2M | ||
| Q4 24 | $18.1M | $170.7M | ||
| Q3 24 | $5.3M | $130.9M | ||
| Q2 24 | $10.7M | $143.5M | ||
| Q1 24 | $12.9M | $106.5M |
自由现金流MLABST
| Q4 25 | $18.0M | $151.9M | ||
| Q3 25 | $7.1M | $136.2M | ||
| Q2 25 | $884.0K | $115.5M | ||
| Q1 25 | $11.9M | $86.6M | ||
| Q4 24 | $17.3M | $138.9M | ||
| Q3 24 | $3.5M | $91.3M | ||
| Q2 24 | $9.9M | $98.4M | ||
| Q1 24 | $12.3M | $64.4M |
自由现金流率MLABST
| Q4 25 | 27.7% | 16.6% | ||
| Q3 25 | 11.7% | 14.6% | ||
| Q2 25 | 1.5% | 12.2% | ||
| Q1 25 | 19.2% | 9.5% | ||
| Q4 24 | 27.6% | 15.3% | ||
| Q3 24 | 6.0% | 9.3% | ||
| Q2 24 | 16.9% | 9.5% | ||
| Q1 24 | 21.0% | 6.4% |
资本支出强度MLABST
| Q4 25 | 1.1% | 5.4% | ||
| Q3 25 | 1.8% | 2.5% | ||
| Q2 25 | 1.7% | 2.7% | ||
| Q1 25 | 1.2% | 3.6% | ||
| Q4 24 | 1.3% | 3.5% | ||
| Q3 24 | 3.1% | 4.0% | ||
| Q2 24 | 1.5% | 4.4% | ||
| Q1 24 | 0.9% | 4.2% |
现金转化率MLABST
| Q4 25 | 5.17× | 3.19× | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | 2.32× | ||
| Q1 25 | — | 1.70× | ||
| Q4 24 | — | 29.50× | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | 2.00× | ||
| Q1 24 | — | 1.40× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
ST
暂无分部数据
